|
1
|
Gartrell BA, Coleman R, Efstathiou E,
Fizazi K, Logothetis CJ, Smith MR, Sonpavde G, Sartor O and Saad F:
Metastatic prostate cancer and the bone: Significance and
therapeutic options. Eur Urol. 68:850–858. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Crawford ED, Higano CS, Shore ND, Hussain
M and Petrylak DP: Treating patients with metastatic castration
resistant prostate cancer: A comprehensive review of available
therapies. J Urol. 194:1537–1547. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Halabi S, Kelly WK, Ma H, Zhou H, Solomon
NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, et
al: Meta-analysis evaluating the impact of site of metastasis on
overall survival in men with castration-resistant prostate cancer.
J Clin Oncol. 34:1652–1659. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Oster G, Lamerato L, Glass AG, Richert-Boe
KE, Lopez A, Chung K, Richhariya A, Dodge T, Wolff GG, Balakumaran
A and Edelsberg J: Natural history of skeletal-related events in
patients with breast, lung, or prostate cancer and metastases to
bone: a 15-year study in two large US health systems. Support Care
Cancer. 21:3279–3286. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Borras JM, Lievens Y, Dunscombe P, Coffey
M, Malicki J, Corral J, Gasparotto C, Defourny N, Barton M,
Verhoeven R, et al: The optimal utilization proportion of external
beam radiotherapy in European countries: An ESTRO-HERO analysis.
Radiother Oncol. 116:38–44. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Borras JM, Barton M, Grau C, Corral J,
Verhoeven R, Lemmens V, van Eycken L, Henau K, Primic-Zakelj M,
Strojan P, et al: The impact of cancer incidence and stage on
optimal utilization of radiotherapy: Methodology of a population
based analysis by the ESTRO-HERO project. Radiother Oncol.
116:45–50. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nieder C, Pawinski A, Haukland E, Dokmo R,
Phillipi I and Dalhaug A: Estimating need for palliative external
beam radiotherapy in adult cancer patients. Int J Radiat Oncol Biol
Phys. 76:207–211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Norwegian Directorate of Health, Oslo, .
2015, National care program with guidelines for the examinations,
treatments and follow up of patients with prostate cancer.
https://helsedirektoratet.no/Documents/Utgåtte%20publikasjoner/IS-1777%20(1)%20Prostatakreft%2017.12.09-16-10.12.pdfAccessed
on June 26, 2016. (In Norwegian).
|
|
9
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et
al: Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zielinski RR, Azad AA, Chi KN and
Tyldesely S: Population-based impact on overall survival after the
introduction of docetaxel as standard therapy for metastatic
castration resistant prostate cancer. Can Urol Assoc J.
8:E520–E523. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
deBono JS, Oudard S, Ozguroglu M, Hansen
S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L,
et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic
castration-resistant prostate cancer progressing after docetaxel
treatment: A randomised open-label trial. Lancet. 376:1147–1154.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
deBono JS, Logothetis CJ, Molina A, Fizazi
K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, et al:
Abiraterone and increased survival in metastatic prostate cancer. N
Engl J Med. 364:1995–2005. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ryan CJ, Smith MR, Fizazi K, Saad F,
Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small
EJ, et al: Abiraterone acetate plus prednisone versus placebo plus
prednisone in chemotherapy-naive men with metastatic
castration-resistant prostate cancer (COU-AA-302): Final overall
survival analysis of a randomised, double-blind, placebo-controlled
phase 3 study. Lancet Oncol. 16:152–160. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Scher HI, Fizazi K, Saad F, Taplin ME,
Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et
al: Increased survival with enzalutamide in prostate cancer after
chemotherapy. N Engl J Med. 367:1187–1197. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Loriot Y, Miller K, Sternberg CN, Fizazi
K, De Bono JS, Chowdhury S, Higano CS, Noonberg S, Holmstrom S,
Mansbach H, et al: Effect of enzalutamide on health-related quality
of life, pain, and skeletal-related events in asymptomatic and
minimally symptomatic, chemotherapy-naive patients with metastatic
castration-resistant prostate cancer (PREVAIL): Results from a
randomised, phase 3 trial. Lancet Oncol. 16:509–521. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Murphy JD, Nelson LM, Chang DT, Mell LK
and Le QT: Patterns of care in palliative radiotherapy: A
population-based study. J Oncol Pract. 9:e220–e227. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fizazi K, Carducci M, Smith M, Damião R,
Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, et al:
Denosumab versus zoledronic acid for treatment of bone metastases
in men with castration-resistant prostate cancer: A randomised,
double-blind study. Lancet. 377:813–822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Parker C, Nilsson S, Heinrich D, Helle SI,
O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, et
al: Alpha emitter radium-223 and survival in metastatic prostate
cancer. N Engl J Med. 369:213–223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jong JM, Oprea-Lager DE, Hooft L, de Klerk
JM, Bloemendal HJ, Verheul HM, Hoekstra OS and van den Eertwegh AJ:
Radiopharmaceuticals for palliation of bone pain in patients with
castration-resistant prostate cancer metastatic to bone: A
systematic review. Eur Urol. pii:S0302–2838, 00862-00863. 2015.
|
|
20
|
Norum J, Traasdahl ER, Totth A, Nieder C
and Olsen JA: Health economics and radium-223 (Xofigo®)
in the treatment of metastatic castration resistant prostate cancer
(mCRPC): A case history and a systematic review of the literature.
Glob J Health Sci. 8:1–9. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sweeney CJ, Chen YH, Carducci M, Liu G,
Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, et
al: Chemohormonal therapy in metastatic hormone-sensitive prostate
cancer. N Engl J Med. 373:737–746. 2015. View Article : Google Scholar : PubMed/NCBI
|
